Type 2 diabetes is the most common cause of end-stage renal disease in the United States,
and type 2 diabetes has been shown to be a myocardial infarction equivalent in regard to …

The review by Wilmer et al.(1) and the comments from Brenner (2) reflect the dilemma facing
physicians regarding the optimal approach to the blockade of the renin-angiotensin system …

Background: Previous studies seem to show different effects of angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) on cardiovascular (CV) …

OBJECTIVES: National guidelines recommend angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin receptor blockers (ARBs) therapy for diabetic patients with …

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been
used extensively for preventing cardiovascular and renal complications in patients with …

Importance Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with …

Background/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin
II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains …

BACKGROUND: Diabetes causes 45% of incident end‐stage renal disease (ESRD). Risk of
progression is higher in those with clinical risk factors (albuminuria and hypertension), and …

Objective: The efficacy of angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in reducing cardiovascular outcomes in patients with diabetes and overt …

Introduction: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor
blockers (ARBs) are widely used to block the renin-angiotensin system (RAS). Yet it remains …